NCT01575301

DIabetes REsearCh on Patient sTratification (DIRECT): GLP-1R Agonists

• Status: Completed
• Phase: N/A
• Study type: Interventional
• Enrollment: 411 (actual)
• Sponsor: University of Dundee · Academic / Other
• Sex: All
• Age: 18 Years – 80 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to collect a cohort of patients treated with GLP-1R Agonists and to assess phenotypic, genetic and genomic biomarkers of glycaemic response to these agents.

Detailed description

To develop a cohort of patients treated with GLP-1 R Agonists who are phenotyped at baseline and at 6 month follow up to determine clinical, imaging and other biomarker predictors of glycaemic response to GLP-1R Agonists. The hypothesis is that one, or a combination, of these biomarkers is associated with glycaemic response to GLP-1R Agonists. The primary outcome is therefore HbA1c reduction after 6 months of GLP-1R A treatment. This is a cohort study of 800 patients being treated with either exenatide or liraglutide for 6 months, and carried out in 4 UK centres.

Conditions

• Diabetes

Interventions

Type	Name	Description
DRUG	Exenatide, Liraglutide	Dosage, frequency and duration not specified by protocol

Timeline

• Start date: 2011-03-01
• Primary completion: 2015-07-01
• Completion: 2015-12-11
• First posted: 2012-04-11
• Last updated: 2018-04-11

Locations

4 sites across 1 country: United Kingdom